NCT06703463View on ClinicalTrials.gov

A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 17, 2023

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2024

Conditions
Healthy
Interventions
DRUG

MK-1167

Administered via oral capsule per dosing regimen.

DRUG

Diltiazem

Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules.

Trial Locations (1)

68502

Celerion (Site 0002), Lincoln

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06703463 - A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006) | Biotech Hunter | Biotech Hunter